Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Vebreltinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Apollomics and LaunXP partner on Vebreltinib development
    Apollomics and LaunXP partner on Vebreltinib development

    31 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/31/3052245/0/en/Apollomics-and-LaunXP-Announce-Development-and-Commercialization-Agreement-for-Vebreltinib.html

    GLOBENEWSWIRE
    31 Mar 2025
    Share Share
    Apollomics Presents Vebreltinib Data At ESMO Congress 2024
    Apollomics Presents Vebreltinib Data At ESMO Congress 2024

    16 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/16/2946593/0/en/Apollomics-Presents-Vebreltinib-Data-in-Patients-with-Non-Small-Cell-Lung-Cancer-with-METex14-Skipping-Mutations-at-European-Society-for-Medical-Oncology-ESMO-Congress-2024.html

    GLOBENEWSWIRE
    16 Sep 2024
    Share Share
    Apollomics Reports Positive Data For Vebreltinib In Solid Tumors
    Apollomics Reports Positive Data For Vebreltinib In Solid Tumors

    13 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/13/2929124/0/en/Apollomics-Announces-Positive-Preliminary-Data-of-Vebreltinib-in-Patients-with-Non-CNS-MET-Fusion-Solid-Tumors-from-its-Phase-2-SPARTA-Trial.html

    GLOBENEWSWIRE
    13 Aug 2024
    Share Share
    Apollomics: Vebreltinib Data At ASCO 2024
    Apollomics: Vebreltinib Data At ASCO 2024

    04 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/04/2893001/0/en/Apollomics-Announces-Vebreltinib-Data-at-the-2024-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html

    GLOBENEWSWIRE
    04 Jun 2024
    Share Share
    Avistone: Vebreltinib Approved in China for Rare Brain Glioma
    Avistone: Vebreltinib Approved in China for Rare Brain Glioma

    25 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240425029482/en

    BUSINESSWIRE
    25 Apr 2024
    Share Share
    Apollomics' Vebreltinib Approved in China for MET+ Gliomas
    Apollomics' Vebreltinib Approved in China for MET+ Gliomas

    25 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/25/2869647/0/en/Apollomics-Announces-Approval-of-Vebreltinib-in-China-as-a-First-in-Class-Treatment-for-Gliomas-with-MET-Fusion-Gene.html

    GLOBENEWSWIRE
    25 Apr 2024
    Share Share